OncoMatch/Clinical Trials/NCT02000089
The Cancer of the Pancreas Screening-5 CAPS5)Study
Is NCT02000089 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Secretin for pancreas cancer.
Treatment: Secretin — Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: BRCA2 germline mutation
Confirmed germline mutation carrier (BRCA2, ...)
Required: CDKN2A germline mutation
FAMMM (CDKN2A/p16)
Required: PALB2 germline mutation
Confirmed germline mutation carrier (PALB2)
Required: BRCA1 germline mutation
Confirmed germline mutation carrier (BRCA1)
Required: ATM germline mutation
Confirmed germline mutation carrier (ATM)
Required: MLH1 germline mutation
Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM)
Required: MSH2 germline mutation
Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM)
Required: PMS2 germline mutation
Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM)
Required: MSH6 germline mutation
Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM)
Required: EPCAM germline mutation
Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM)
Required: PRSS1 germline mutation
Confirmed germline mutation carrier (PRSS1)
Required: PRSS2 germline mutation
Confirmed germline mutation carrier (PRSS2)
Required: SPINK1 germline mutation
Confirmed germline mutation carrier (SPINK1)
Required: CFTR germline mutation
Confirmed germline mutation carrier (CFTR)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale University · New Haven, Connecticut
- Johns Hopkins Hospital · Baltimore, Maryland
- Dana Farber Cancer Center, Harvard University · Boston, Massachusetts
- University of Michigan · Ann Arbor, Michigan
- NYU Langone Medical Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02000089 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require BRCA2?
Yes, BRCA2 germline mutation is a required biomarker for enrollment.
Does this trial require CDKN2A?
Yes, CDKN2A germline mutation is a required biomarker for enrollment.
Does this trial require PALB2?
Yes, PALB2 germline mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages